306 related articles for article (PubMed ID: 32292497)
1. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
2. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
3. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.
Hoang ML; Chen CH; Sidorenko VS; He J; Dickman KG; Yun BH; Moriya M; Niknafs N; Douville C; Karchin R; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Sci Transl Med; 2013 Aug; 5(197):197ra102. PubMed ID: 23926200
[TBL] [Abstract][Full Text] [Related]
4. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
5. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
6. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
[TBL] [Abstract][Full Text] [Related]
8. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
9. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
Boot A; Jiang N; Rozen SG
Theranostics; 2020; 10(12):5578-5580. PubMed ID: 32373232
[TBL] [Abstract][Full Text] [Related]
10. Molecular aspects of upper tract urothelial carcinoma.
Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.
Fang D; Zhang L; Li X; Xiong G; Chen X; Han W; He Z; Zhou L
J Cancer Res Clin Oncol; 2014 Mar; 140(3):477-85. PubMed ID: 24469253
[TBL] [Abstract][Full Text] [Related]
12. Distinguishing characteristics of urothelial carcinoma in kidney transplant recipients between China and Western countries.
Liu GM; Fang Q; Ma HS; Sun G; Wang XC
Transplant Proc; 2013; 45(6):2197-202. PubMed ID: 23747184
[TBL] [Abstract][Full Text] [Related]
13. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway.
Chen IH; Luo HL; Su YL; Huang CC; Chiang PH; Yu CC; Lee NL; Lin JJ; Sung MT
Molecules; 2019 Oct; 24(20):. PubMed ID: 31619002
[TBL] [Abstract][Full Text] [Related]
14. Mutational signature and clonal relatedness of recurrent urothelial carcinomas with aristolochic acid.
Zhu J; Ai Q; Cheng Q; Shen D; Dong Z; Li J; Shen D; Wang W; Zhang X; Li H
Front Oncol; 2022; 12():990023. PubMed ID: 36185218
[TBL] [Abstract][Full Text] [Related]
15. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
16. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
18. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure.
Nortier JL; Schmeiser HH; Muniz Martinez MC; Arlt VM; Vervaet C; Garbar CH; Daelemans P; Vanherweghem JL
Nephrol Dial Transplant; 2003 Feb; 18(2):426-8. PubMed ID: 12543902
[No Abstract] [Full Text] [Related]
19. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy.
Shan H; Tian W; Hong Y; Xu B; Wang C; Yu B; Wang X
BMC Complement Med Ther; 2020 Jun; 20(1):166. PubMed ID: 32493345
[TBL] [Abstract][Full Text] [Related]
20. High Level of Aristolochic Acid Detected With a Unique Genomic Landscape Predicts Early UTUC Onset After Renal Transplantation in Taiwan.
Lai HY; Wu LC; Kong PH; Tsai HH; Chen YT; Cheng YT; Luo HL; Li CF
Front Oncol; 2021; 11():828314. PubMed ID: 35071023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
